Biological therapies for inflammatory pouch disorders: insights and outcomes from the RESERVO study of GETECCU - PubMed
5 hours ago
- #Crohn's disease of the pouch
- #pouchitis
- #biological therapy
- Biological therapies are effective for inflammatory pouch disorders, including pouchitis, Crohn's Disease of the Pouch (CDP), and cuffitis.
- The RESERVO study evaluated 145 patients, with 62% being men and a median age of 54 years.
- Clinical remission rates at 12 months were similar across different biologics: infliximab (45%), adalimumab (44%), golimumab (43%), vedolizumab (39%), and ustekinumab (45%).
- Vedolizumab showed better results as a first-line therapy compared to subsequent lines (50% vs 33%).
- After anti-TNF failure, switching to another mechanism of action is recommended due to higher risks of failure and discontinuation with a second anti-TNF.
- The study highlights the importance of biological therapy in managing refractory inflammatory pouch disorders.